奧地利因斯布魯克癌癥研究中心13日發(fā)表公報(bào)說,，該中心科學(xué)家開展的實(shí)驗(yàn)顯示，與其他癌癥類型相比,，現(xiàn)有抗體療法更適用于乳腺癌,、腎癌,、肝癌和膀胱癌。
許多癌癥都有一個(gè)共同特點(diǎn),，即癌細(xì)胞表面有一種名為“EpCAM”的蛋白,。不久前，一種可攻擊“EpCAM”蛋白的抗體被發(fā)現(xiàn),，目前一些醫(yī)院正在對(duì)其展開臨床試驗(yàn),。但什么樣的患者適合接受這種抗體療法，醫(yī)學(xué)界還不清楚,。
奧地利因斯布魯克癌癥研究中心的科學(xué)家運(yùn)用免疫組織化學(xué)法，通過抗體染色來標(biāo)注相關(guān)的蛋白,，對(duì)2000多個(gè)癌組織樣品展開分析,。結(jié)果發(fā)現(xiàn)，與其他癌癥類型相比,，現(xiàn)有的抗體療法更適用于乳腺癌,、腎癌、肝癌和膀胱癌,。
科學(xué)家表示,，免疫組織化學(xué)法的優(yōu)點(diǎn)是操作簡單，費(fèi)用不高,。在對(duì)患者采取抗體療法前,，利用免疫組織化學(xué)法弄清楚患者癌細(xì)胞表面“EpCAM”蛋白的情況，將會(huì)使治療更具針對(duì)性,，并減輕其副作用給患者造成的痛苦,。（生物谷Bioon.com）
生物谷推薦原文出處：
J Clin Pathol doi:10.1136/jcp.2011.090274
EpCAM expression in primary tumour tissues and metastases: an immunohistochemical analysis
Gilbert Spizzo1,2,3, Dominic Fong1,2, Martin Wurm1,2, Christian Ensinger4, Peter Obrist5, Carina Hofer4, Guido Mazzoleni6, Guenther Gastl1,2, Philip Went7
Abstract
Aims Epithelial cell adhesion molecule (EpCAM) is a cell surface protein with oncogenic features that is expressed on healthy human epithelia and corresponding malignant tumours. EpCAM expression frequently correlates with more aggressive tumour behaviour and new EpCAM-specific therapeutic agents have recently been approved for clinical use in patients with cancer. However, no consensus exists on how and when to evaluate EpCAM expression in patients with cancer.
Material and methods EpCAM expression was assessed by a well-established immunohistochemical staining protocol in 2291 primary tumour tissues and in 108 metastases using the EpCAM-specific antibody clone VU1D9. A total immunostaining score was calculated as the product of a proportion score and an intensity score. Four expression subgroups (no, weak, moderate and intense) were defined. As described previously, the term ‘EpCAM overexpression’ was reserved for tissues showing a total immunostaining score >4.
Results EpCAM was highly expressed in most tumours of gastrointestinal origin and in some carcinomas of the genitourinary tract. However, hepatocellular carcinomas, clear cell renal cell cancer, urothelial cancer and squamous cell cancers were frequently EpCAM negative. EpCAM expression in breast cancer depended on the histological subtype; lobular histology usually showed no or weak expression. Most metastases were EpCAM positive and they frequently reflected the expression phenotype of the primary tumour.
Conclusion EpCAM expression was detected on adenocarcinomas of various primary sites. If EpCAM-specific antibodies are intended to be used in patients with cancer, we recommend prior immunohistochemical evaluation of EpCAM expression, particularly in patients with renal cell cancer, hepatocellular carcinoma, urothelial carcinoma, breast cancer and squamous cell carcinomas.
